

Bajaj Finserv

Estimate change



TP change



Rating change



Bloomberg	BJFIN IN
Equity Shares (m)	1601
M.Cap.(INRb)/(USD\$)	3247.7 / 34
52-Week Range (INR)	2195 / 1597
1, 6, 12 Rel. Per (%)	12/8/6
12M Avg Val (INR M)	2349

Financials & Valuations (INR b)

Y/E March	2026	2027E	2028E
Consol.			
Revenue	1,505	1,786	2,068
Adj. PAT	98	127	145
BAF			
NII	441	543	669
PAT	193	265	327
BLife			
APE	85	100	117
VNB margin (%)	19.2	20.5	21.0
EV	253	287	328
BGen			
NEP	95	107	119
CoR (%)	102.8	102.1	101.1
PAT	19	22	26
Valuation			
Adj. EPS (INR)	61	79	91
EPS growth (%)	10.3	29.1	14.5
P/E (x)	33.1	25.6	22.4
BVPS (INR)	325	377	436
P/B (x)	6.2	5.4	4.7
RoE (%)	13.0	15.0	14.9

Shareholding pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	58.7	58.7	58.8
DII	12.1	11.8	10.1
FII	7.0	7.4	8.5
Others	22.2	22.2	22.6

FII includes depository receipts

CMP: INR2,029

TP: INR2,490 (+23%)

Upgrade to Buy

Strong performance across subsidiaries

- Bajaj Finserv (BJFIN) reported consolidated revenue of INR420.4b (+19% YoY) and PAT of INR31.3b (+12% YoY) in 1QFY27.
- Bajaj General (BGen) reported 11% YoY growth with respect to GWP at INR57.9b (in line). NEP grew 20% YoY to INR26.7b (14% beat). PAT at INR4.8b declined 28% YoY (13% beat due to higher investment income).
- Bajaj Life (BLife) reported 30% YoY growth in APE to INR17.1b (10% beat). VNB witnessed strong growth of 87% YoY to INR2.7b (46% beat), resulting in a VNB margin of 15.9%, up 480bp YoY (MOFSL of 12%).
- BGen is awaiting a normalization in trends before accelerating in the motor segment. BLife has achieved a sustainable product mix, with 22-25% in par, 22-25% in non-par, 45% in ULIP, and rising contribution from protection. Capital infusion will continue in Bajaj Finserv Health (BFH) for the next 5-6 quarters, while Bajaj Finserv Direct (BFD) will achieve breakeven in FY28.
- In BGen, we have largely maintained NEP estimates but increased our PAT estimates by 4%/6% in FY27/FY28, driven by stronger investment performance. In BLife, we have increased our VNB margin estimate by 50bp for FY27. On a consolidated basis, we have increased BJFIN's EPS estimates by 10%/11% for FY27/28, given BAF's strong performance.
- Supported by improving trends across its established lending and insurance subsidiaries, along with rising profitability in new businesses, we believe BJFIN is well placed to capitalize on the financial ecosystem opportunity. We recently upgraded BAF to BUY ([Link](#)) and **are now upgrading BJFIN to BUY with a TP of INR2,490 (based on SoTP).**

BGen – Pressure in the motor and fire segments

- GWP performance in 1Q rose 11% YoY, with the motor segment growing 8% YoY amid high competitive pressure. Retail health/group health maintained their double-digit growth trajectory, with GWP growing 34%/36% YoY.
- Motor continued to contribute the highest to the GWP mix at 32% in 1QFY27 (33% in 1QFY26), followed by the commercial segment at 25% (33% in 1QFY26). Health (retail + group + govt) contributed 31% to the mix, compared to 23% in 1QFY26.
- Brokers remained the largest contributor to GWP (49% in 1QFY27 from 55% in 1QFY26), followed by individual agents (15%, same as 1QFY26). Banca channel contributed 9% (8% in 1QFY26), aided by new partnerships.
- The claim ratio increased YoY to 74.3% (vs. 71.1% in 1QFY26) vs our estimate (70.5%). The rise in claims ratio was largely driven by an increase in the motor OD claims ratio to 76.6% (74.9% in 1QFY26) and the health claims ratio to 89.2% (82.8% in 1QFY26).
- Combined ratio at 104.7% increased 110bp YoY (vs. our est. of 102.0%).

Research Analyst: Prayesh Jain (Prayesh.Jain@MotilalOswal.com) | Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: Kartikeya Mohata (Kartikeya.Mohata@MotilalOswal.com) | Muskan Chopra (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

BLife – Margin expansion led by a product mix shift

- BLife's APE growth of 30% YoY in 1QFY27 was on the back of 17% YoY growth in individual APE and 322% YoY growth in group APE.
- Within individual APE, annuity (10% of APE) was the fastest-growing segment, with APE increasing more than 2.5x YoY. Protection (10% of APE) witnessed 57% YoY growth, followed by 17% YoY growth in ULIP (39% of APE) and 12% YoY growth in Par (18% of APE). Non-par savings (10% of APE) declined 32% YoY.
- The rising share of annuity and protection, along with rising rider attachment, led to VNB margin expansion from 11.1% in 1QFY26 to 15.9% in 1QFY27.
- Channel contribution for agency/banca/direct channels stood at 38%/50%/12%.

Emerging subsidiaries

- BFD reported revenue of INR1.1b (up 21% YoY), maintaining its sequential growth trajectory following the completion of the platform migration. The loss stood at INR370m compared to INR500m in 1QFY26.
- BFH reported revenue of INR2.3b (down 5% YoY), with over 6m transactions completed on the platform. The loss stood at INR440m compared to INR430m in 1QFY26.
- Bajaj Finserv AMC (BFAMC) reported revenue of INR250m and loss of INR410m, with AUM at INR314.4b by the end of 1QFY27.

Key highlights from the management commentary

- The recent Supreme Court ruling on motor TP claims has limited immediate implications, and BGen is monitoring future judicial developments before revisiting its reserving methodology.
- Riders attached to both term and savings products currently account for around 22% of NOPs, with management aiming to steadily increase rider penetration going forward.
- Beyond the AMC, management expects additional capital requirements to build its alternatives franchise and the proposed reinsurance business.

Valuation and view

- BJFIN is operating in a phase where growth is increasingly broad-based, with BAF providing earnings stability, insurance businesses transitioning into margin-led, value-accretive growth, and new digital platforms moving closer to scale and breakeven.
- Improved execution across life and general insurance, alongside disciplined capital allocation in emerging subsidiaries, is expected to enhance visibility on consolidated value creation over the medium term.
- In BGen, we have largely maintained NEP estimates but increased our PAT estimates by 4%/6% in FY27/FY28, driven by stronger investment performance. In BLife, we have increased our VNB margin estimate by 50bp for FY27. On a consolidated basis, we have increased BJFIN's EPS estimates by 10%/11% for FY27/28, given BAF's strong performance.
- Supported by improving trends across its established lending and insurance subsidiaries, along with rising profitability in new businesses, we believe BJFIN is well placed to capitalize on the financial ecosystem opportunity. We recently upgraded BAF to BUY ([Link](#)) and **are now upgrading BJFIN to BUY with a TP of INR2,490 (based on SoTP).**

Exhibit 1: SoTP valuation

	Value (INRb)	Basis
Bajaj Finance	8,083	❖ 4.8x FY28E P/B
Stake	51.3%	
BAF value	4,147	
Bajaj General	645	❖ 25x FY28E PAT
Stake	77.3%	
BGen value	499	
Bajaj Life	394	❖ 1.2x FY28E EV
Stake	77.3%	
BLife value	305	
Emerging businesses value	19	❖ 2x FY25 P/B
Total value	4,970	
Holdco discount	20%	
BJFIN Value	3,976	
No. of shares	1598.7	
TP	2,490	

Financial Highlights

Financial Highlights														
INRb	FY26				FY27				FY26	FY27E	1Q FY27E	act v/s Est. (%)	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE						
Consolidated														
Total Income	355	374	395	385	420	439	448	479	1,505	1,786	391	7%	19%	9%
Adj PAT	28	22	20	25	31	31	32	32	98	127	28	14%	12%	23%
BGen														
GWP	52.0	64.1	73.9	43.2	57.9	69.3	80.2	48.1	233.3	255.5	56.2	3%	11%	34%
NEP	22.3	24.0	24.6	24.3	26.7	27.6	27.1	25.9	95.2	107.3	23.5	14%	20%	10%
Underwriting Profit	-1.2	-0.9	-1.4	-1.0	-1.3	-0.2	-1.4	-1.0	-4.4	-3.8	-0.9			
PAT	6.6	5.2	4.0	3.7	4.8	5.6	5.5	6.8	19.4	21.9	4.2	13%	-28%	31%
Loss Ratio (%)	71.1	75.8	75.1	68.1	74.3	75.5	74.5	66.7	72.6	72.8	70.5	380	321	618
Combined Ratio (%)	103.6	102.3	97.9	113.6	104.7	99.5	97.5	110.8	102.8	102.1	102.0	270	107	-887
BLife														
APE	13.1	21.5	21.3	29.0	17.1	25.8	24.5	33.1	84.9	100.4	15.5	10%	30%	-41%
VNB	1.5	3.7	4.1	7.1	2.7	4.8	4.9	8.2	16.3	20.6	1.9	46%	87%	-62%
VNB Margin (%)	11.1	17.1	19.0	24.5	15.9	18.5	20.0	24.8	19.2	20.5	12.0	389	482	-857

Change in estimates

INRb	New		Old		Change in estimates	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Consol.						
Revenue	1,786	2,068	1,751	2,015	2.0	2.6
Adj. PAT	127	145	120	137	5.1	5.7
BAF						
NII	543	669	538	667	0.9	0.3
PAT	265	327	253	319	4.4	2.4
BLife						
APE	100	117	98	111	2.8	5.1
VNB margin (%)	20.5	21.0	20.0	21.0	50.0	0.0
EV	287	328	286	326	0.4	0.7
BGen						
NEP	107	119	105	117	1.8	1.8
Combined ratio (%)	102.1	101.1	101.5	101.1	58.6	8.8
PAT	22	26	21	24	3.9	5.8
Valuation						
Adj. EPS (INR)	79	91	72	82	9.9	11.1



Key highlights from the management commentary

Bajaj General

- The recent Supreme Court ruling on motor TP claims has limited immediate implications, and the company is monitoring future judicial developments before revisiting its reserving methodology.
- Bajaj General already maintains a conservative reserving philosophy and is well positioned to absorb any adverse outcomes. Additionally, GIC has filed a review petition against the judgment.
- The company continues to engage with the regulator regarding a revision in motor TP premium rates.
- Combined ratio continues to outperform the industry, supported by disciplined underwriting and prudent business selection. Robust reinsurance program provides adequate protection against NATCAT events
- The crop insurance business is expected to grow in FY27, backed by the tender wins for this year.
- The government health portfolio, which operated under a 2+1-year contract, is also due for renewal during the year.
- Under IFRS, the most significant impact for the general insurance business will arise from changes in the accounting treatment of acquisition costs. In addition, long-duration liabilities, particularly the motor TP book, will move from an undiscounted to a discounted valuation basis, resulting in a meaningful reserve release at transition.
- IFRS will require insurers writing loss-making contracts to recognize expected losses upfront, leading to greater earnings transparency across the industry.
- The company has adopted a cautious stance in the motor segment by moderating growth, but intends to accelerate expansion once pricing and claims trends stabilize.

Bajaj Life

- Demand for annuity products continues to strengthen, supported by favorable demographic trends and the growing retirement planning needs of India's 50+ population.
- While non-par savings demand has remained relatively subdued, management expects the segment to enter an upcycle over the coming quarters.
- The MFI business has witnessed a healthy recovery, aided by 20 new partnerships added over the last 15 months.
- Retail protection has increased meaningfully, with contribution rising from 8.5% to 12%. Management expects growth to normalize following the strong expansion seen over the last few quarters.
- The product mix has now reached a sustainable level, comprising 22-25% par, 22-25% non-par, around 45% ULIPs, with the balance contributed by protection products.
- Customer engagement in protection continues to improve, with 34% of customers purchasing term plans during the quarter, while 16% opted for enhanced riders, supporting both ticket sizes and profitability.

- Riders attached to both term and savings products currently account for around 22% of NOPs, with management aiming to steadily increase rider penetration going forward.

Bajaj Finserv Health

- Revenue declined during the quarter due to business restructuring undertaken to comply with evolving regulatory requirements.
- The company continues to invest aggressively in technology capabilities and network expansion, with these investments expected to begin delivering returns from next year onwards.
- Capital infusion into the business will continue over the next six quarters, with planned investments of approximately INR2-3b.

Bajaj Finserv Markets


- Industry-wide credit quality concerns that persisted over the past 2-3 years have started easing, as lending partners have progressively tightened underwriting standards and improved portfolio quality.
- The business was originally expected to achieve breakeven during 3Q/4QFY26. However, profitability was delayed due to the ongoing CRM platform transformation, implementation of RBI digital lending guidelines, and the transition toward a trail-based commission model.
- Management now expects the platform to achieve full-year breakeven in FY27.

Bajaj Finserv AMC

- The AMC business will require incremental capital to support future growth.
- Beyond the mutual fund platform, management also expects additional capital requirements for building its alternatives franchise and the proposed reinsurance business.


Key exhibits

Exhibit 2: BJFIN revenue grew 19% YoY in 1QFY27




Source: MOFSL, Company

Exhibit 3: BJFIN's PAT grew 12% YoY in 1QFY27




Source: MOFSL, Company

Exhibit 4: BGen's GWP rose 11% YoY




Source: MOFSL, Company

Exhibit 5: Profitability ratio trends of BGen




Source: MOFSL, Company

Exhibit 6: Underwriting profitability trends




Source: MOFSL, Company

Exhibit 7: BGen's PAT trends




Source: MOFSL, Company

Exhibit 8: BGen's product mix (%)




Source: MOFSL, Company

Exhibit 9: BGen's channel mix (%)




Source: MOFSL, Company

Exhibit 10: BLife's APE grew 30% YoY in 1QFY27




Source: MOFSL, Company

Exhibit 11: VNB margin expanded to 24.5%




Source: MOFSL, Company

Exhibit 12: BLife's product mix




Source: MOFSL, Company

Exhibit 13: BLife's channel mix




Source: MOFSL, Company

Exhibit 14: Persistency trends




Source: MOFSL, Company

Exhibit 15: Solvency ratio




Source: MOFSL, Company

Exhibit 16: BFH revenue and PAT




Source: MOFSL, Company

Exhibit 17: BFD revenue and PAT




Source: MOFSL, Company

Exhibit 18: BFAMC AUM and revenue



Source: MOFSL, Company

Exhibit 19: One-year forward valuation of BJFIN



Source: MOFSL, Company

Financials and valuations

Consolidated income statement

INRb	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Interest income	265	269	313	402	538	674	800	936	1,100
Fees and commission income	25	24	30	43	54	54	68	86	104
Insurance operating income	245	258	314	359	463	555	631	711	806
Other income	9	55	27	17	48	55	6	52	58
Total income	544	606	684	821	1,104	1,338	1,505	1,786	2,068
Employee expenses	48	47	66	88	104	121	141	169	195
Finance costs	93	91	95	122	184	243	282	337	429
Fees and commission expense	22	26	34	42	70	87	107	123	136
Impairment of financial instruments	41	60	49	32	46	79	95	87	92
Claims paid	125	119	164	166	218	247	267	301	340
Other insurance related expenses	89	128	117	137	198	243	252	309	338
Other expenses	42	36	47	66	70	81	88	102	114
Total expenses	461	507	572	653	890	1,101	1,233	1,428	1,644
PBT	83	99	113	168	214	237	269	358	424
Tax	23	25	30	46	58	62	72	93	110
PAT	60	74	83	122	156	176	197	265	314
Adj. PAT	34	45	46	64	81	89	98	127	145

Consolidated Balance Sheet

INRb	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
EQUITY AND LIABILITIES									
Equity share capital	1	1	1	2	2	2	2	2	2
Reserves and surplus	312	358	402	462	602	722	778	902	1,044
Non-controlling interest	196	225	261	312	434	560	631	769	938
Net worth	509	583	663	776	1,038	1,284	1,410	1,672	1,983
Borrowings	1,010	982	1,259	1,631	2,239	2,798	3,569	3,926	4,805
Deposits	214	258	308	447	602	714	685	822	987
Insurance contract liabilities	588	752	856	941	1,183	1,347	1,478	1,626	1,951
Other liabilities	193	226	251	260	319	379	443	492	555
Total liabilities	2,005	2,219	2,674	3,279	4,342	5,238	6,175	6,867	8,298
Equity and liability	2,514	2,802	3,337	4,055	5,379	6,522	7,585	8,539	10,282
ASSETS									
Loans	1,417	1,471	1,919	2,427	3,267	4,085	5,000	6,312	7,858
Investments	817	918	1,137	1,192	1,362	1,684	1,901	1,944	1,651
Fixed assets	22	22	25	31	40	45	47	51	56
Cash and bank balance	25	34	44	54	124	157	176	68	31
Other assets	232	356	213	351	586	551	460	163	685
Total assets	2,514	2,802	3,337	4,055	5,379	6,522	7,585	8,539	10,282

Financials and valuations

Valuation

INR	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
EPS	21	28	29	40	51	56	61	79	91
P/E (x)	95.8	72.2	70.8	50.4	39.7	36.5	33.1	25.6	22.4
BVPS	318	365	415	485	649	803	882	1,046	1,241
P/B (x)	6.4	5.6	4.9	4.2	3.1	2.5	2.3	1.9	1.6

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	$\geq 15\%$
SELL	$< -10\%$
NEUTRAL	$-10\% \text{ to } 15\%$
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.